2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

Avelumab-Based Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (AURA Oncodistinct-004): A Phase 2 Multicenter Clinical Trial - Beyond the Abstract

The phase 2 AURA trial is the first to demonstrate that neoadjuvant immunotherapy can be safely combined with dose-dense MVAC (ddMVAC), achieving high efficacy.

In parallel, the phase 3 NIAGARA trial recently demonstrated a survival benefit with peri-operative durvalumab plus neoadjuvant gemcitabine–cisplatin. Given that ddMVAC is a well-established alternative to gemcitabine–cisplatin and is widely used across Europe, demonstrating its safety in combination with immunotherapy paves the way for future phase 3 trials investigating neoadjuvant or perioperative immunotherapy in combination with this regimen.

Written by: Jérémy Blanc,1 Aurélien Carnot,2 Philippe Barthélémy,3 Vinciane Casert,4 Brieuc Sautois,5 Jan Van den Brande,6 Vincent Vanhaudenarde,7 Lionel Staudacher,8 Emmanuel Seront,9 Veronique Debien,1 Lieveke Ameye,10 Nuria Kotecki,1 Françoise Rothé,11 Sandrine Rorive,12 Jean-Christophe Fantoni,13 Thibault Tricard,14 Thierry Roumeguère,15,16 Ahmad Awada,1 Nieves Martinez Chanza1

  1. Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
  2. Medical Oncology Department, Centre Oscar Lambret, Lille, France.
  3. Medical Oncology Department, ICANS, Strasbourg, France.
  4. Medical Oncology Department, Centre Hospitalier Universitaire Ambroise Paré, Mons, Belgium.
  5. Medical Oncology Department, CHU de Liège Hôpital du Sart Tilman, Liège, Belgium.
  6. Medical Oncology Department, University Hospital Antwerp, Edegem, Belgium.
  7. Medical Oncology Department, CHU UCL Namur, Namur, Belgium.
  8. Medical Oncology Department, Hôpital Paris Saint-Joseph, Paris, France.
  9. Medical Oncology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  10. Clinical Trials Center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
  11. Breast Cancer Translational research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
  12. Pathology Department, CurePath, Jumet, Belgium.
  13. Urology Department, Centre Hospitalier Universitaire de Lille, Lille, France.
  14. Urology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  15. Urology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
  16. Urology Department, Hôpital Erasme, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
Read the Abstract